Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines
Cancer Research Journal
Volume 2, Issue 2, March 2014, Pages: 29-32
Received: Feb. 10, 2014; Published: Mar. 30, 2014
Views 2542      Downloads 208
Authors
Torricelli Piera, Department SPES, University of Molise, Campobasso, Italy
Antonelli Francesco, Department of Biology, University of Tor Vergata, Rome, Italy
Ferorelli Pasquale, Department of Biology, University of Tor Vergata, Rome, Italy
De Martino Angelo, Department of Biology, University of Tor Vergata, Rome, Italy; IURS Santa Rita, Rome, Italy
Shevchenko Anna, People’s Friendship University of Russia, Moscow, Russia
Beninati Simone, Department of Biology, University of Tor Vergata, Rome, Italy
Article Tools
PDF
Follow on us
Abstract
A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy
Keywords
Food Supplements, (ER)+/(ER)- Breast Cancers, Cancer Cell Survival
To cite this article
Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, Beninati Simone, Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines, Cancer Research Journal. Vol. 2, No. 2, 2014, pp. 29-32. doi: 10.11648/j.crj.20140202.13
References
[1]
Carter B. S., Beaty T. H., Steinberg G. D., Childs B. & Walsh P. C. Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 3367–3371.
[2]
Muraca L, Leung D, Clark A, Beduz MA, Goodwin P. Breast cancer survivors: taking charge of lifestyle choices after treatment. Eur J Oncol Nurs. 2011;15(3):250-253.
[3]
Meiyanto E, Hermawan A, Anindyajati. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents.Asian Pac J Cancer Prev. 2012;13(2):427-436.
[4]
Arcangeli S., Pinzi V., Arcangeli G. Epidemiology of prostate cancer and treatment remarks. World J. Radiol. 2012;4:241–246.
[5]
Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy.Nat Rev Drug Discov. 2013;12(12):931-947.
[6]
Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL, Granados-Principal S, Lorente JA, Quiles JL.Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies.Crit Rev Oncol Hematol. 2011;80(3):347-368.
[7]
Antonelli F & Beninati S. Enhanced survival of B16-F10 melanoma tumour-bearing C57BL6/N mice treated with a mixture of antioxidants in: Recent Res Devel in Life Sci. 2011;5:51-60 Research Signpost, Trivandrum India
[8]
Keawpradub N, Amooquaye E.E, Burke PJ, Houghton PJ. Cytotoxic activity of indole alkaloids from Alstonia macrophylla. Planta Medica 1999;65: 311–315.
[9]
Skehan P, Storeng R, Scudiero D, Monks A, McMahon I, Vistica D, Waren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer drug screening. Journal of National Cancer Institute. 1990: 82:1107–1112.
[10]
Lipsett MB. Prospects in endocrinology for chemotherapy. Cancer Res. 1969;29(12):2408-2411.
[11]
Jensen EV, and Jacobson H. I. Basic Guides to the Mechanism of Estrogen Action. Recent Progr. Hormone Res.1962;18: 387-408.
[12]
Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008;8(9):1377-1385.
[13]
Klepin HD, Geiger AM, Bandos H, Costantino JP, Rapp SR, Sink KM, Lawrence JA, Atkinson HH, Espeland MA. Cognitive Factors Associated with Adherence to Oral Antiestrogen Therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Study.Cancer Prev Res (Phila). 2014;7(1):161-168.
[14]
Osborne CK, McGuire WL.Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med. 1979;130(5):401-407.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186